title: Hyperprolactinemia in men with asthenozoospermia, oligozoospermia, or azoospermia.
abstract: The role of serum prolactin (PRL) in male infertility is still unclear. To assess the clinical significance of PRL determination during infertility studies, serum hormones and semen samples from 167 men attending the Andrology Clinic were analyzed, and PRL seric values were correlated with volume, sperm count, motility, viability, and morphology. The range of PRL levels (ng/mL) was 7.3 +/- 2.1 in the control group (n = 46), 13.9 +/- 6.6 in asthenozoospermic (n = 51), 12.6 +/- 7.8 in oligozoospermic (n = 42), and 10.9 +/- 4.8 in azoospermic patients (n = 28). Significantly higher (p < .0001) levels of PRL were found in the men with asthenozoospermia, oligozoospermia, and azoospermia. In the 121 infertile patients with abnormal semen analysis, serum PRL levels were below 14.0 ng/mL (normal mean + 3 SD) in 81 (66.9%) and above this level in 40 (33.1%) cases. Serum FSH and LH concentrations in azoospermic men were significantly higher (p < .0001) when compared with those of the control group, which indicates some disturbance of the spermatogenic process, and estradiol was significantly higher (p < .02) in oligozoospermic patients. No significant differences were found in serum testosterone. Twenty-one patients with idiopathic oligoasthenozoospermia and hyperprolactinemia were treated with 2.5 mg of bromocriptine daily for 6 months, resulting in a nonmeasurable effect on their sperm analysis. In conclusion, two-thirds of patients with oligozoospermia, asthenozoospermia, and azoospermia have normal PRL levels. Infertility in men due to moderate hyperprolactinemia could be associated with these sperm disturbances, but bromocriptine was of no therapeutic utility.
authors.affiliation: Gynecology Endocrinology/Andrology Section, Hospital de Gineco Obstetricia Luis Castelazo Ayala, Instituto Mexicano del Seguro Social, México, DF, México.
authors.forename: G
authors.initials: G
authors.lastname: Merino
authors.forename: S
authors.initials: S
authors.lastname: Carranza-Lira
authors.forename: J C
authors.initials: JC
authors.lastname: Martinez-Chéquer
authors.forename: E
authors.initials: E
authors.lastname: Barahona
authors.forename: C
authors.initials: C
authors.lastname: Morán
authors.forename: J A
authors.initials: JA
authors.lastname: Bermúdez
mesh_terms: D000328:Adult; D001971:Bromocriptine / Q000627:therapeutic use; D012739:Gonadal Steroid Hormones / Q000097:blood; D006727:Hormone Antagonists / Q000627:therapeutic use; D006801:Humans; D006966:Hyperprolactinemia / Q000097:blood* / Q000188:drug therapy; D007248:Infertility, Male / Q000097:blood* / Q000188:drug therapy; D008297:Male; D009845:Oligospermia / Q000097:blood* / Q000188:drug therapy; D012661:Semen / Q000166:cytology; D013076:Sperm Count; D013081:Sperm Motility / Q000502:physiology
chemical_list: D012739:Gonadal Steroid Hormones; D006727:Hormone Antagonists; D001971:Bromocriptine